Home › Dermatitis › California
Dermatitis clinical trials in California
6 studies for Dermatitis are looking for participants at sites in California.
Cities in California
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Fountain Valley
- Novartis Investigative Site, Los Angeles
- Novartis Investigative Site, Sacramento
- and 2 more
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Sep 28, 2026 · NCT06947993First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Alliance Clinical West Hills (Focus Clinical Research), West Hills
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07527923A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
- Investigational Drug Service - Rady Childrens Hospital-San Diego, San Diego
- University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm, San Diego
RecruitingPhase 3
Ages 6 to 11 · All sexes · Updated Sep 25, 2026 · NCT06807268A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
- Northridge Clinical Trials, Northridge
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 4, 2026 · NCT07765888A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Marvel Research, LLC, Huntington Beach
- Metropolis Dermatology, Los Angeles
- Dermatology Research Associates, Los Angeles
- and 4 more
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Aug 28, 2026 · NCT07599813A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 1, Lancaster
- Inmagene Site 23, Los Angeles
RecruitingPhase 2
Ages 18 to 74 · All sexes · Updated Aug 12, 2026 · NCT07037901From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.